Abstract
Background: Thromboxane (TX) A2 is a pro-thrombotic prostanoid synthesized by activated platelets, biotransformed
into 11-dehydro-TXB2, measurable in urines. Eleven-dehydro-TXB2 excretion is increased in high risk
cardiovascular diseases; however, this cardiovascular biomarker awaits validation in large trials. The need of
large urine volume (8 - 10 mL) and the unknown stability of 11-dehydro-TXB2 in urine after collection might limit
its implementation.
Methods: We scaled the original method for urine extraction and 11-dehydro-TXB2 measurement down to 1 mL,
and assessed its stability at 4°C or 25°C up to 6 days after collection. The sensitivity of the 1 mL procedure was also
tested in aspirin-treated patients with low 11-dehydro-TXB2 excretion.
Results: The 1 mL adapted method was highly correlated with the original assay (rho = 0.98, p < 0.001, n = 33).
Both methods showed similar recoveries in samples spiked with exogenous 11-dehydro-TXB2. Urinary 11-dehydro-
TXB2 values in samples immediately frozen were comparable and highly correlated to values in samples at
4°C (day 6: rho = 0.99, p > 0.001, n = 8) or 25°C (day 6: rho = 0.98, p < 0.001, n = 23) up to 6 days in controls and
patients.
Conclusions: Eleven-dehydro-TXB2 can be measured in small urine volumes and is relatively stable for a few days
after collection, even at 25°C. These data allow the validation of this non-invasive cardiovascular biomarker in
large studies.
Lingua originale | English |
---|---|
pagine (da-a) | 105-111 |
Numero di pagine | 7 |
Rivista | Clinical Laboratory |
Volume | 2014 |
DOI | |
Stato di pubblicazione | Pubblicato - 2014 |
Keywords
- platelets
- thromboxane